A prospective, observational study of fidaxomicin use for <i>Clostridioides difficile</i> infection in France
Benoît Guéry(Université de Lille), Florent Wallet(Université Claude Bernard Lyon 1), Pierre Berger, Vincent Cattoir(Inserm), R. Gauzit(Hôpital Cochin), Marion Levast, Aurélien Dinh(Université Paris-Saclay), Emilie Bessède, O. Rogeaux, Jean‐Philippe Lavigne(Inserm), Lionel Piroth(CHU Dijon Bourgogne), Thiérry Prazuck(Université d'Orléans), Magali Gourdon, D. Descamps(Centre National de la Recherche Scientifique), Anne Vachée, Yohan N’Guyen(Centre Hospitalier Universitaire de Reims), Alban Le Monnier(Université Paris-Saclay), C. Couzigou, Fabrice Camou(Hôpital Saint-André), Anne‐Laure Roux(CHU Ambroise Paré), Véronique Leflon‐Guibout, Joy Mootien(Centre Hospitalier de Mulhouse), Catherine Lechiche, Véronique Vernet Garnier(Sorbonne Université), DAFNE study group, C. Laurans, Frédéric Barbut(Sorbonne Université), Pascale Bémer(Centre Hospitalier Universitaire de Nantes)
Cited by 7
Related Papers
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
|Science|2020|3.2k
How to manage Pseudomonas aeruginosa infections
|Drugs in Context|2018|743
European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults
|Clinical Microbiology and Infection|2021|615
Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage
|Science|2020|382
Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008
|Eurosurveillance|2008|286